Art

J-GLOBAL ID：201802267677625811   Reference number：18A0856893

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

二次治療としてダサチニブを投与した慢性骨髄性白血病患者におけるダサチニブ中止試験の最終3年間の結果【JST・京大機械翻訳】

Author (48)： Okada Masaya (Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan) ,  Imagawa Jun (Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan) ,  Tanaka Hideo (Department of Hematology, Hiroshima City Asa Hospital, Hiroshima, Japan) ,  Nakamae Hirohisa (Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan) ,  Hino Masayuki (Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan) ,  Murai Kazunori (Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan) ,  Ishida Yoji (Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan) ,  Kumagai Takashi (Department of Hematology, Ohme Municipal General Hospital, Tokyo, Japan) ,  Sato Seiichi (Department of Internal Medicine, Fujimoto General Hospital, Miyakonojo, Japan) ,  Ohashi Kazuteru (Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan) ,  Sakamaki Hisashi (Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan) ,  Wakita Hisashi (Division of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan) ,  Uoshima Nobuhiko (Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan) ,  Nakagawa Yasunori (Department of Hematology, Japanese Red Cross Medical Centre, Tokyo, Japan) ,  Minami Yosuke (Division of Blood Transfusion/Division of Medical Oncology and Haematology, Kobe University Hospital, Kobe, Japan) ,  Ogasawara Masahiro (Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan) ,  Takeoka Tomoharu (Division of Hematology and Immunology, Otsu Red Cross Hospital, Otsu, Japan) ,  Akasaka Hiroshi (Department of Hematology, Shinko Hospital, Kobe, Japan) ,  Utsumi Takahiko (Department of Hematology, Shiga Medical Centre for Adults, Moriyama, Japan) ,  Uike Naokuni (Division of Hematology, National Kyushu Cancer Centre, National Hospital Organization, Fukuoka, Japan) ,  Sato Tsutomu (Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan) ,  Ando Sachiko (Department of Haematology, Teine Keijinkai Hospital, Sapporo, Japan) ,  Usuki Kensuke (Division of Haematology, NTT Medical Centre Tokyo, Tokyo, Japan) ,  Mizuta Syuichi (Division of Haematology, Fujita Health University, Aichi, Japan) ,  Hashino Satoshi (Department of Hematology, Hokkaido University Hospital, Sapporo, Japan) ,  Nomura Tetsuhiko (Department of Internal Medicine, Hyogo Prefectural Awaji Medical Center, Hyogo, Japan) ,  Shikami Masato (Department of Hematology, Daiyukai General Hospital, Aichi, Japan) ,  Fukutani Hisashi (Department of Hematology, Aichi Cancer Center Aichi Hospital, Aichi, Japan) ,  Ohe Yokiko (Department of Hematology, Uegahara Hospital, Hyogo, Japan) ,  Kosugi Hiroshi (Department of Hematology, Ogaki Municipal Hospital, Gifu, Japan) ,  Shibayama Hirohiko (Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan) ,  Maeda Yasuhiro (Department of Hematology, National Hospital Organization Osaka-Minami Medical Center, Osaka, Japan) ,  Fukushima Toshihiro (Department of Hematology and Immunology, Kanazawa Medical University Hospital, Ishikawa, Japan) ,  Yamazaki Hirohito (Department of Hematology and Oncology, Kanazawa University Hospital, Ishikawa, Japan) ,  Tsubaki Kazuo (Department of Hematology, Nara Hospital Kinki University, Nara, Japan) ,  Kukita Toshimasa (Department of Hematology, Imamura Hospital, Kagoshima, Japan) ,  Adachi Yoko (Department of Internal Medicine, Japan Community Health Care Organization, Kobe Central Hospital, Kobe, Japan) ,  Nataduka Toshiki (Department of Internal Medicine, Shinseikai Toyama Hospital, Toyama, Japan) ,  Sakoda Hiroto (Department of Hematology, Sumitomo Hospital, Osaka, Japan) ,  Yokoyama Hisayuki (Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan) ,  Okamoto Takahiro (Department of Hematology, Takarazuka City Hospital, Hyogo, Japan) ,  Shirasugi Yukari (Department of Hematology and Oncology, Tokai University, Kanagawa, Japan) ,  Onishi Yasushi (Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan) ,  Nohgawa Masaharu (Department of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan) ,  Yoshihara Satoshi (Department of Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Hyogo, Japan) ,  Morita Satoshi (Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan) ,  Sakamoto Junichi (NPO Epidemiological and Clinical Research Information Network (ECRIN), Okazaki, Japan) ,  Kimura Shinya (Division of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan)
Material： Clinical Lymphoma Myeloma and Leukemia
Volume： 18  Issue： 5  Page： 353-360.e1  Publication year： 2018 
JST Material Number： W3263A  ISSN： 2152-2650  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： We previously reported an inte...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0856893&from=J-GLOBAL&jstjournalNo=W3263A") }}

Thesaurus term： Recurrence ,  median value ,  *therapy ,  *chronic myeloid leukemia ,  Safety ,  follow-up study ,  *patient ,  NK cell ,  remission ,  risk factor ,  Japan ,  regulatory T cell ,  imatinib resistance

Author keywords (5)： CML ,  DADI ,  Natural killer cell ,  Stop trial ,  Treatment-free remission

JST classification (2)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (2)： Imatinib ,  Dasatinib

Terms in the title (7)： 二次治療 ,  ダサチニブ ,  投与 ,  慢性骨髄性白血病 ,  患者 ,  中止 ,  試験